Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Hypertelorism	NCIT_C34715	[A condition in which there is an abnormally increased distance between two organs or bodily parts; most often, this term is referring to an increased distance between the orbits (orbital hypertelorism).]
Hypertropia	NCIT_C34716	[Vertical strabismus in which there is permanent upward deviation of the visual axis of one eye.]
Remnant Hyperlipidemia	NCIT_C34710	[A laboratory test result indicating a type of inherited dysbetalipoproteinemia in which the triglyceride and total cholesterol concentrations are increased and the high-density lipoprotein concentration is decreased.]
Fredrickson Type IV Lipidemia	NCIT_C34711	[A laboratory test result indicating an autosomal dominant condition in which there is increased very low density lipoprotein production, which leads to increased triglyceride concentration.]
Oropharyngeal (p16-Negative) Carcinoma by AJCC v8 Stage	NCIT_C132994	[A term that refers to the staging of p16-negative oropharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.]
Pharyngeal Carcinoma by AJCC v8 Stage	NCIT_C132814	[A term that refers to the staging of pharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.]
Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8	NCIT_C132995	[Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)]
Stage 0 Pharyngeal Cancer	NCIT_C4942	[Stage 0 carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.]
Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8	NCIT_C132996	[Stage I includes: T1, N0, M0. T1: Tumor 2 cm or smaller in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)]
Insulin Coma	NCIT_C34730	[A hypoglycemia-induced comatose state resulting from a large dose of exogenous insulin.]
Coma	NCIT_C34497	[A state of profound unconsciousness associated with markedly depressed cerebral activity. Causes include central nervous system damage, intoxication, and metabolic abnormalities.]
Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8	NCIT_C132997	[Stage II includes: T2, N0, M0. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)]
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8	NCIT_C132998	[Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). M0: No distant metastasis. (AJCC 8th ed.)]
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8	NCIT_C132999	[Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4b: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)]
Rilimogene Galvacirepvec/Rilimogene Glafolivec	NCIT_C132990	[A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.]
Fowlpox Virus Vaccine	NCIT_C2521	[A recombinant virus-based vaccine that contains various peptide antigens. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Strong CD8 T cell responses may be induced after prolonged immunization and have been associated with tumor regression.]
p53-HDM2 Protein-protein Interaction Inhibitor APG-115	NCIT_C132991	[An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor APG-115 binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.]
Sintilimab	NCIT_C132992	[A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.]
Gallium Ga 68-NODAGA-E(c[RGDyK])2	NCIT_C132993	[A radiopharmaceutical agent composed of a dimeric cyclic arginine-glycine-aspartic acid (RGD)-based peptide (c[RGDyK]) and labeled, via the chelating agent 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), with gallium Ga 68, with potential alphaVbeta3 (aVb3) integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). After intravenous administration of gallium Ga 68-NODAGA-E(c[RGDyK])2, the cyclic RGD moiety targets and binds to aVb3 integrin which is expressed on the cell membrane of tumor cells and tumor-resident endothelial cells. Upon imaging, aVb3 integrin-expressing cells can be visualized and expression levels can be quantified. This can be used to assess response to anti-angiogenic treatment. aVb3 integrin is overexpressed on certain tumor cells and tumor-resident endothelial cells, while minimally or not expressed on healthy, normal cells; aVb3 integrin plays a key role in angiogenesis, tumor proliferation and survival.]
Inguinal Hernia without Mention of Obstruction or Gangrene	NCIT_C34728	[The protrusion of abdominal cavity contents through the inguinal canal, without mention of obstruction or necrosis of the herniated contents.]